Raymond James lowered the firm’s price target on Abbott to $116 from $123 and keeps an Outperform rating on the shares. Abbott’s stock has been "noisy," contributing to year-to-date underperformance, and the firm sees a more tempered CV-environment, the analyst tells investors in a research note. The firm’s view of Abbott as a 6%-7% top-line grower and a 10%+ EPS grower, excluding CV-testing, has not changed, it said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott Laboratories (ABT) Q1 Earnings Cheat Sheet
- Abbott says FDA clears reader for FreeStyle Libre 3 system
- Needham med tech analysts to hold an analyst/industry conference call
- Abbott says no FreeStyle Libre readers being physically recalled
- FDA Classifies Abbott’s (NYSE:ABT) Freestyle Libre Readers Recall as the Most Serious Type